Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

Last updated: November 11, 2021
Sponsor: The Cooper Health System
Overall Status: Active - Recruiting

Phase

4

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT03906617
18039
  • Ages 18-90
  • All Genders

Study Summary

This study will assess analgesia after robotic lung surgery. Subjects will be randomized to receive wound infiltration and intercostal nerve block with either liposomal bupivacaine or bupivacaine/epinephrine + dexamethasone. Liposomal bupivacaine is a newer local anesthetic product and has not been compared to a combination of bupivacaine/epinephrine + dexamethasone in the context of pain control after robotic lung surgery.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • undergoing robotic wedge resection or lobectomy for lung mass(es)

Exclusion

Exclusion Criteria:

  • emergency case
  • history of opiate abuse
  • chronic pain syndrome
  • intravenous drug use
  • chronic use of oral steroids
  • pregnancy
  • imprisonment
  • body weight lower than 70 kg
  • liver failure
  • uninsured patients
  • non-verbal patients or patients who are unable to rate their pain on a visual analoguepain scale
  • history of allergic reaction to any of the drugs used in the study: bupivacaine,liposomal bupivacaine, dexamethasone

Study Design

Total Participants: 34
Study Start date:
April 10, 2019
Estimated Completion Date:
June 10, 2022

Connect with a study center

  • Cooper University Hospital

    Camden, New Jersey 08103
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.